Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow^® CS

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease, 2020 report. Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed June 26, 2020.
   Google Scholar
• SullivanJ, PravosudV, ManninoDM, SiegelK, ChoateR, SullivanT. National and state estimates of COPD morbidity and mortality - United States, 2014–2015. Chronic Obstr Pulm Dis. 2018;5(4):324–333. doi:10.15326/jcopdf.5.4.2018.015730723788
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention - National Center for Health Statistics. Chronic obstructive pulmonary disease (COPD) Includes: chronic bronchitis and emphysema. Available from: https://www.cdc.gov/nchs/fastats/copd.htm. Accessed 129, 2019.
   Google Scholar
• FordES, MurphyLB, KhavjouO, GilesWH, HoltJB, CroftJB. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. Chest. 2015;147(1):31–45. doi:10.1378/chest.14-097225058738
   PubMed Web of Science ®Google Scholar
• BraidoF, ChrystynH, BaiardiniI, et al. “Trying, but failing” - the role of inhaler technique and mode of delivery in respiratory medication adherence. J Allergy Clin Immunol Pract. 2016;4(5):823–832. doi:10.1016/j.jaip.2016.03.00227587316
   PubMed Web of Science ®Google Scholar
• Sunovion Pharmaceuticals Inc. LONHALA™ MAGNAIR™ (glycopyrrolate) inhalation solution for oral inhalation use. Prescribing information. 12, 2018 Available from: https://www.lonhalamagnair.com/LonhalaMagnair-Prescribing-Information.pdf. Accessed 514, 2019.
   Google Scholar
• Sunovion Pharmaceuticals Inc. MAGNAIR™ Nebulizer system instructions for use. 12, 2017 Available from: https://www.lonhalamagnair.com/LonhalaMagnair-Instructions-for-Use.pdf. Accessed 514, 2019.
   Google Scholar
• PhamS, FergusonGT, KerwinE, GoodinT, WheelerA, BauerA. In vitro characterization of the eFlow closed system nebulizer with glycopyrrolate inhalation solution. J Aerosol Med Pulm Drug Deliv. 2018;31(3):162–169. doi:10.1089/jamp.2017.138429125918
   PubMed Web of Science ®Google Scholar
• FergusonGT, GoodinT, TosielloR, WheelerA, KerwinE. Long-term safety of glycopyrrolate/eFlow® CS in moderate-to-very-severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study. Respir Med. 2017;132:251–260. doi:10.1016/j.rmed.2017.08.02028919143
   PubMed Web of Science ®Google Scholar
• KerwinE, DonohueJF, GoodinT, TosielloR, WheelerA, FergusonGT. Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. Respir Med. 2017;132:238–250. doi:10.1016/j.rmed.2017.07.01128838685
   PubMed Web of Science ®Google Scholar
• KerwinEM, DonohueJF, FergusonGT, GanapathyV, Ozol-GodfreyA, RajagopalanK. Satisfaction with the use of eFlow closed-system nebulizer in patients with moderate-to-very severe chronic obstructive pulmonary disease: Findings from a long-term safety study. J Aerosol Med Pulm Drug Deliv. 2019;32(1):24–33. doi:10.1089/jamp.2018.147730457433
   PubMed Web of Science ®Google Scholar
• JonesP, JenkinsC, BauerleO, on behalf of the CAT Development Steering Group. COPD Assessment Test (CAT) healthcare professional user guide. Issue 3. 2, 2012 Available from: https://www.lungemedicin.dk/fagligt/skemaer/142-cathcp-vejledning/file.html. Accessed 516, 2019.
   Google Scholar
• JonesPW, HardingG, BerryP, WiklundI, ChenWH, Kline LeidyN. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.0010250919720809
   PubMed Web of Science ®Google Scholar
• PaladiniL, HodderR, CecchiniI, BelliaV, IncalziRA. The MRC dyspnoea scale by telephone interview to monitor health status in elderly COPD patients. Respir Med. 2010;104(7):1027–1034. doi:10.1016/j.rmed.2009.12.01220116231
   PubMed Web of Science ®Google Scholar
• HodderR, PriceD. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat® Soft Mist™ Inhaler. Int J Chron Obstruct Pulmon Dis. 2009;4:381–390. doi:10.2147/COPD.S339119888356
   PubMedGoogle Scholar
• ChrystynH, SmallM, MilliganG, HigginsV, GilEG, EstruchJ. Impact of patients’ satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med. 2014;108(2):358–365. doi:10.1016/j.rmed.2013.09.02124209768
   PubMed Web of Science ®Google Scholar
• AminAN, GanapathyV, RoughleyA, SmallM. Confidence in correct inhaler technique and its association with treatment adherence and health status among US patients with chronic obstructive pulmonary disease. Patient Prefer Adherence. 2017;11:1205–1212. doi:10.2147/PPA.S14013928744110
   PubMed Web of Science ®Google Scholar
• JaradN. Chronic obstructive pulmonary disease (COPD) and old age? Chron Respir Dis. 2011;8(2):143–151. doi:10.1177/147997231140721821596895
   PubMed Web of Science ®Google Scholar
• TaffetGE, DonohueJF, AltmanPR. Considerations for managing chronic obstructive pulmonary disease in the elderly. Clin Interv Aging. 2014;9:23–30. doi:10.2147/CIA.S5299924376347
   PubMed Web of Science ®Google Scholar
• RoglianiP, CalzettaL, CoppolaA, et al. Optimizing drug delivery in COPD: The role of inhaler devices. Respir Med. 2017;124:6–14. doi:10.1016/j.rmed.2017.01.00628284323
   PubMed Web of Science ®Google Scholar
• DhandR, DolovichM, ChippsB, MyersTR, RestrepoR, FarrarJR. The role of nebulized therapy in the management of COPD: Evidence and recommendations. COPD. 2012;9(1):58–72. doi:10.3109/15412555.2011.63004722292598
   PubMedGoogle Scholar